CH Biotech R&D Co., Ltd. (6534) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of CH Biotech R&D Co., Ltd. stock TWD 97.05, price TWD 85.50, upside +13.5%, quality 78 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 34.64 TWD – 114.48 TWD · fair‑value band 59.36 TWD – 126.17 TWD · the 85.50 TWD price screens below the 97.05 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow CH Biotech R&D Co. in your weekly email
Every Wednesday you see whether CH Biotech R&D Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CH Biotech R&D Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of agriculture chemicals in Taiwan, the United States, and internationally. It offers fertilizers, biostimulants, and plant growth regulators; and provides biotechnology services.
Show moreShow less
The company was incorporated in 2013 and is headquartered in Nantou City, Taiwan.
Stock analysis
CH Biotech R&D Co., Ltd. (6534) currently trades at 85.50 TWD, while our model-based Fair Value estimate is 97.05 TWD, implying the stock looks roughly 12% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 101.82 TWD per share, and 11 of the 26 models we run sit above the 85.50 TWD price.
Bear case: the Asset-Based group reads lowest at 17.78 TWD, and 15 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 59.36 TWD (bear) to 126.17 TWD (bull), the price of 85.50 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 78/100 (high quality), in the Basic Materials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
CH Biotech R&D Co., Ltd. reported revenue of 1.8B TWD in FY2025 versus 1.0B TWD in FY2021, a compound +15.6%/yr. Reported net income was 464M TWD in FY2025, compounding +12.3%/yr from FY2021.
Key figures
Market cap 8.6B TWD (≈ $263M) Micro · P/E ratio 14.5 · P/S ratio 4.60 · EPS (TTM) 5.89 TWD · Dividend yield 6.2% · Net margin 32.3% · Return on equity 22.8% · Return on assets (EBIT) 15.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 87 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at 4% fair-value upside, at 14%, 6534 screens cheaper than that median.
Fair Value models
Bear59.36 TWDFair Value 97.05 TWDBull126.17 TWD
Price 85.50 TWD · Upside +13.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.4982 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+24.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.3%
Dividend (yield on the price)6.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 34%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +11.5% a year for the price.
Compare CH Biotech R&D Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 162 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score78 · Top 25%
Fair Value upside+13.5% · Above median
Profitability
Return on equity (12 months)22.8% · Top 25%
Return on assets13.0% · Top 25%
Net margin (12 months)32.3% · Top 25%
Operating margin (12 months)37.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)9.3% · Above median
Dividend yield (12 months)6.2% · Top 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Agricultural Inputs median · lower = cheaper
P/E (12 months)14.5× · Cheaper than median
P/B3.21× · Priciest 25%
P/S (12 months)4.60× · Priciest 25%
Price / free cash flow (fiscal year)18.5× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is CH Biotech R&D Co., Ltd. (6534) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 97.05 TWD versus a price of 85.50 TWD, about +14% upside (undervalued).
What is the fair value of 6534?
Our model-based fair value for CH Biotech R&D Co., Ltd. is 97.05 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 85.50 TWD.
What is the quality score of 6534?
CH Biotech R&D Co., Ltd. has a Quality Score of 78/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CH Biotech R&D Co., Ltd. (6534)?
Our model-based price target is the fair value of 97.05 TWD (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 59.36 TWD, optimistic scenario 126.17 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the CH Biotech R&D Co., Ltd. stock forecast for 2026?
Our models put fair value at 97.05 TWD, about +14% upside versus a price of 85.50 TWD (undervalued). Cautious scenario 59.36 TWD, optimistic scenario 126.17 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of CH Biotech R&D Co., Ltd. (6534)?
CH Biotech R&D Co., Ltd. reported trailing-twelve-month revenue of about 1.9B TWD (latest available figure, as of Nov 8, 2026).
Does CH Biotech R&D Co., Ltd. pay a dividend?
CH Biotech R&D Co., Ltd. currently shows a dividend yield of 6.21% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of CH Biotech R&D Co., Ltd. (6534) and when is the ex-dividend date?
CH Biotech R&D Co., Ltd. pays a dividend of 5.31 TWD per share a year, a dividend yield of 6.2%. The last ex-dividend date was Sep 1, 2026. A dividend has been paid every year since at least 2016. The payout ratio is 90.1% of earnings. Free cash flow covers the dividend 0.87 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into CH Biotech R&D Co., Ltd. (6534)?
For today's price to be fair in a discounted-cash-flow model, CH Biotech R&D Co., Ltd. would have to grow free cash flow by +13.3 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.0 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 6534 use?
Our models discount CH Biotech R&D Co., Ltd. at 11.8 %: a base by market capitalisation (micro), damped by beta 0.17, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CH Biotech R&D Co., Ltd. that is +13.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has CH Biotech R&D Co., Ltd. (6534) delivered so far?
Over the past 5 years revenue at CH Biotech R&D Co., Ltd. grew +21.0 % a year. The price currently implies free-cash-flow growth of +13.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CH Biotech R&D Co., Ltd. (6534) growing?
The median revenue growth in the sector is +11.2 % a year. That is the yardstick for the growth priced into CH Biotech R&D Co., Ltd. (+13.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CH Biotech R&D Co., Ltd. (6534)?
The free-cash-flow yield on the price is 5.40 %: that much free cash flow CH Biotech R&D Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CH Biotech R&D Co., Ltd. (6534)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CH Biotech R&D Co., Ltd. it is 97.05 TWD per share (as of Nov 8, 2026), against a price of 85.50 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is CH Biotech R&D Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 6534 trades below its calculated fair value: price 85.50 TWD, fair value 97.05 TWD, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6534?
No. The price is what the market pays today (85.50 TWD); the fair value is what the company's own numbers justify (97.05 TWD). For CH Biotech R&D Co., Ltd. the two are 11.55 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is CH Biotech R&D Co., Ltd. worth?
The market values CH Biotech R&D Co., Ltd. at about 8.6B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 85.50 TWD; our models calculate a fair value of 97.05 TWD per share.
What do the bullish and bearish scenarios say about 6534?
Our models span a range for CH Biotech R&D Co., Ltd.: cautious scenario 59.36 TWD, base 97.05 TWD, optimistic 126.17 TWD per share (as of Nov 8, 2026, price 85.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6534?
CH Biotech R&D Co., Ltd. trades at a price-to-earnings ratio of 14.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 97.05 TWD is built from several models across several years. Other multiples: P/B 3.2, P/S 4.6, EV/EBITDA 9.5.
How solid is the balance sheet of CH Biotech R&D Co., Ltd. (6534)?
Balance-sheet figures for CH Biotech R&D Co., Ltd. (as of Nov 8, 2026): return on equity 22.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 78/100, which measures business quality independently of the share price.
How far is 6534 from its 52-week high?
CH Biotech R&D Co., Ltd. trades at 85.50 TWD, about 16% below its 52-week high of 102.00 TWD and 13% above the low of 75.84 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 97.05 TWD is for.
Which stocks are comparable to CH Biotech R&D Co., Ltd.?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CH Biotech R&D Co., Ltd. stock attractive at the current price?
The data as of Nov 8, 2026: price 85.50 TWD, calculated fair value 97.05 TWD (+14%), Quality Score 78/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6534 calculated?
We run CH Biotech R&D Co., Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 97.05 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. CH Biotech R&D Co., Ltd. currently trades 12% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CH Biotech R&D Co., Ltd. (6534)?
The closing price on Nov 9, 2026 was 85.50 TWD. Our model-based fair value is 97.05 TWD, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CH Biotech R&D Co., Ltd. right now?
A fairly wide model range (59.36 TWD to 126.17 TWD) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of CH Biotech R&D Co., Ltd.
How large is the market capitalisation of CH Biotech R&D Co., Ltd. (6534)?
The market capitalisation of CH Biotech R&D Co., Ltd. is 8.6B TWD (≈ $263M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CH Biotech R&D Co., Ltd. (6534)?
The price-to-sales ratio of CH Biotech R&D Co., Ltd. is 4.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CH Biotech R&D Co., Ltd. (6534)?
Earnings per share at CH Biotech R&D Co., Ltd. are 5.89 TWD (price ÷ EPS = P/E 14.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CH Biotech R&D Co., Ltd. (6534)?
The dividend yield of CH Biotech R&D Co., Ltd. is 6.2% (payout 90.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CH Biotech R&D Co., Ltd. (6534)?
The net margin of CH Biotech R&D Co., Ltd. is 32.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CH Biotech R&D Co., Ltd. (6534)?
The return on equity (ROE) of CH Biotech R&D Co., Ltd. is 22.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CH Biotech R&D Co., Ltd. (6534)?
On an EBIT basis the return on assets of CH Biotech R&D Co., Ltd. is 15.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CH Biotech R&D Co., Ltd. (6534)?
The operating margin of CH Biotech R&D Co., Ltd. is 37.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CH Biotech R&D Co., Ltd. (6534)?
Revenue at CH Biotech R&D Co., Ltd. is growing +9.3% versus a year earlier (3y avg +8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CH Biotech R&D Co., Ltd. (6534)?
Earnings per share at CH Biotech R&D Co., Ltd. are growing +303% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does CH Biotech R&D Co., Ltd. (6534) carry?
The net debt of CH Biotech R&D Co., Ltd. is 270M TWD (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CH Biotech R&D Co., Ltd. in the live analysis
One click puts CH Biotech R&D Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026